Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye

Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye

AIM: To observe the effect of topical 0.05% cyclosporine A (CsA) on the ocular surface and tear protein lacritin in a botulinum B-induced dry eye rat model. METHODS: A total of 36 female SD rats were randomly divided into 3 groups, botulinum B was injected into the right lacrimal gland of all rats....

Full description

Bibliographic Details
Main Authors:	Fen-Dui Zhang, Zhao-Qin Hao, Wei Gao, Yi-Qiao Xing
Format:	Article
Language:	English
Published:	Press of International Journal of Ophthalmology (IJO PRESS) 2019-02-01
Series:	International Journal of Ophthalmology
Subjects:	0.05% cyclosporine a tear protein lacritin dry eye
Online Access:	http://www.ijo.cn/en_publish/2019/2/20190201.pdf

Similar Items

Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
by: Ho-Yun Kim, et al.
Published: (2018-04-01)

An Experience of Using Cyclosporin 0.05 % (Restasis) in Conjunctival Lymphangiectosia Treatment of Patients With Dry Eye Syndrome
by: S. A. Volik, et al.
Published: (2018-10-01)

Tear lacritin concentrations in canine keratoconjunctivitis sicca
by: Disney, Julia L.
Published: (2018)

Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease
by: María Castro-Rebollo, et al.
Published: (2013-08-01)

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
by: Okumus Seydi, et al.
Published: (2012-08-01)

Clinical observation of cyclosporine eye drops with artificial tears for dry eyes
by: Xue-Bing Yang, et al.
Published: (2016-05-01)

Efficacy of topical cyclosporine 0.05% eye drops in the treatment of dry eyes
by: Haitham Y Al-Nashar
Published: (2015-01-01)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
by: Deveney T, et al.
Published: (2018-03-01)

Topical application of 0.05% cyclosporine A as an adjunct to LASIK
by: E. V. Kudryashova, et al.
Published: (2015-12-01)

Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury
by: Khosrow Jadidi, et al.
Published: (2014-01-01)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
by: Chang Hyun Park, et al.
Published: (2019-06-01)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
by: Rhee MK, et al.
Published: (2017-06-01)

Biosynthesized Multivalent Lacritin Peptides Stimulate Exosome Production in Human Corneal Epithelium
by: Changrim Lee, et al.
Published: (2020-08-01)

Efficacy of topical carboxymethyl cellulose 0.5% and cyclosporine A 0.05% in dry eye syndrome
by: Sangeeta Shah, et al.
Published: (2017-01-01)

Evaluation criterions and establishment of dry eye model of rats induced by BTX-B
by: Hai-Feng Zhu, et al.
Published: (2015-09-01)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
by: Epitropoulos AT, et al.
Published: (2020-07-01)

Changes in tear protein profile in dogs with keratoconjunctivitis sicca following topical treatment using cyclosporine A
by: Metita Sussadee, et al.
Published: (2021-06-01)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
by: Burade V, et al.
Published: (2020-09-01)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
by: Matossian C, et al.
Published: (2021-05-01)

Ophthalmic rosacea – etiology, pathogenesis, new approaches to the therapy
by: T. A. Chekhova, et al.
Published: (2016-07-01)

Topical cyclosporine A for the treatment of dry eye: a randomized clinical study
by: Injy Y ElShazly, et al.
Published: (2021-01-01)

FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
by: D. Y. Maychuk, et al.
Published: (2015-10-01)

Comparing the efficacy of 2% topical rebamipide and 0.1% topical sodium hyaluronate with or without 0.05% topical cyclosporine in patients with dry eye disease
by: Priyanka V Gandhi, et al.
Published: (2021-01-01)

A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops
by: Napoli PE, et al.
Published: (2019-06-01)

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
by: Shaveta Singla, et al.
Published: (2019-01-01)

Effect of 0.5g/L cyclosporine A for symptom and sign scores in patients with moderate to severe dry eye
by: Su-Ying Yu, et al.
Published: (2016-05-01)

Piezoelectric, impedance, electric modulus and AC conductivity studies on (Bi0.5Na0.5)0.95Ba0.05TiO3 ceramic
by: Ansu K. Roy, et al.
Published: (2013-06-01)

A Comparative Study of Efficacy and Safety of Topical Loteprednol Etabonate 0.5% and Cyclosporin A 0.05% for the Treatment of Vernal Keratoconjunctivitis
by: Sharika Ganjoo, et al.
Published: (2020-12-01)

Correlation between paclitaxel Tc > 0.05 and its therapeutic efficacy and severe toxicities in ovarian cancer patients
by: Shuyao Zhang, et al.
Published: (2016-01-01)

Effects of Latanoprost 0.005%/Timolol Maleate 0.5% and Dorzolamide 2%/Timolol Maleate 0.5% Fixed Combinations on 24-hour Intraocular Pressure in Patients with Primary Open-Angle Glaucoma
by: Berna Yüce, et al.
Published: (2012-01-01)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
by: Stonecipher KG, et al.
Published: (2016-05-01)

Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates
by: Betül N. Bayraktutar, et al.
Published: (2016-03-01)

Formulation Considerations for the Management of Dry Eye Disease
by: Priyanka Agarwal, et al.
Published: (2021-02-01)

Novel methods for the evaluation of the tear film in the diagnosis of dry eye
by: Keech, Adam John
Published: (2010)

Novel methods for the evaluation of the tear film in the diagnosis of dry eye
by: Keech, Adam John
Published: (2010)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
by: Hovanesian JA, et al.
Published: (2021-09-01)

Effect of Refresh Plus® preservative-free lubricant eyedrops on tear ferning patterns in dry eye and normal eye subjects
by: Alanazi SA, et al.
Published: (2019-06-01)

Uso de ciclosporina 0,05% tópica no tratamento do olho seco de pacientes portadores do vírus HIV Topical cyclosporine 0.05% for the treatment of dry eye disease in patients infected with the human immunodeficiency virus
by: Rodrigo de Pinho Paes Barreto, et al.
Published: (2009-04-01)

FEATURES OF 0.05% CYCLOSPORINE (RESTASIS) APPLICATION IN TREATMENT OF RECURRENT INFILTRATIVE ADENOVIRAL KERATITIS
by: D. Y. Maychuk, et al.
Published: (2015-10-01)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
by: de Oliveira RC, et al.
Published: (2019-07-01)

Cannot write session to /tmp/vufind_sessions/sess_alp2pb9n9cmtp0olfs89tiuj0g